Melatrax 250 Tablet contains Tranexamic Acid 250 mg, an antifibrinolytic agent used to reduce or prevent excessive bleeding by inhibiting the activation of plasminogen to plasmin, thereby stabilizing formed blood clots. It is commonly prescribed for the management of conditions associated with abnormal bleeding, including heavy menstrual bleeding (menorrhagia), postoperative hemorrhage, dental procedures in patients with bleeding disorders, and hereditary angioedema. Melatrax 250 is also utilized in trauma and surgical settings to minimize blood loss. The tablet is administered orally, with dosage tailored according to the severity of bleeding and patient-specific factors. Tranexamic Acid is generally well-tolerated; however, caution is advised in patients with a history of thromboembolic disorders, as it may increase the risk of thrombosis. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, while rare but serious side effects may involve hypersensitivity reactions and visual disturbances. Melatrax 250 should be used under medical supervision, with appropriate monitoring for efficacy and safety. It is contraindicated in patients with active intravascular clotting and should be used cautiously in those with renal impairment.